Literature DB >> 11225993

Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient.

L M Real1, P Jimenez, A Kirkin, A Serrano, A García, J Cantón, J Zeuthen, F Garrido, F Ruiz-Cabello.   

Abstract

Progressive tumor growth may be associated with suppression of the immune response. Many different mechanisms may contribute to immune evasion. We investigated some of these mechanisms in melanoma cells lines generated from two patients. These cell lines show a complex pattern of altered HLA expression; however, the resulting phenotype did not satisfactorily explain the simultaneous evasion of T and NK cell cytotoxicity. Two additional alterations have now been detected in these melanoma cell lines: (1) resistance to FAS-induced apoptosis caused by defective FAS gene expression, and (2) constitutive expression of immunosuppressive cytokines. Our results show that several of the major mechanisms for immune evasion may coexist in a single tumor. This suggests that tumor progression may give rise to an extremely resistant phenotype, which may be an impediment to some immunotherapeutic strategies. We hypothesize that the simultaneous presence of several mechanisms involved in tumor immune evasion must be the result of progressive selection of characteristics that are advantageous for tumor survival in a competent host. Our findings do not support the possibility that FASL expression is a common mechanism of evasion of immune response in melanoma cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11225993     DOI: 10.1007/s002620000154

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  14 in total

1.  miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis.

Authors:  Avital Gaziel-Sovran; Miguel F Segura; Raffaella Di Micco; Mary K Collins; Douglas Hanniford; Eleazar Vega-Saenz de Miera; John F Rakus; John F Dankert; Shulian Shang; Robert S Kerbel; Nina Bhardwaj; Yongzhao Shao; Farbod Darvishian; Jiri Zavadil; Adrian Erlebacher; Lara K Mahal; Iman Osman; Eva Hernando
Journal:  Cancer Cell       Date:  2011-07-12       Impact factor: 31.743

2.  An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance.

Authors:  Vincenzo Cerullo; Iulia Diaconu; Valentina Romano; Mari Hirvinen; Matteo Ugolini; Sophie Escutenaire; Sirkka-Liisa Holm; Anja Kipar; Anna Kanerva; Akseli Hemminki
Journal:  Mol Ther       Date:  2012-07-24       Impact factor: 11.454

Review 3.  MHC heterogeneity and response of metastases to immunotherapy.

Authors:  Ignacio Algarra; Federico Garrido; Angel M Garcia-Lora
Journal:  Cancer Metastasis Rev       Date:  2021-04-15       Impact factor: 9.264

Review 4.  Immune system: a double-edged sword in cancer.

Authors:  Bodduluru Lakshmi Narendra; Kasala Eshvendar Reddy; Saladi Shantikumar; Sistla Ramakrishna
Journal:  Inflamm Res       Date:  2013-07-19       Impact factor: 4.575

Review 5.  The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon.

Authors:  Robin J Prestwich; Fiona Errington; Rosa M Diaz; Hardev S Pandha; Kevin J Harrington; Alan A Melcher; Richard G Vile
Journal:  Hum Gene Ther       Date:  2009-10       Impact factor: 5.695

Review 6.  Cancer immune escape: MHC expression in primary tumours versus metastases.

Authors:  Federico Garrido; Natalia Aptsiauri
Journal:  Immunology       Date:  2019-10-01       Impact factor: 7.397

7.  Nifetepimine, a dihydropyrimidone, ensures CD4+ T cell survival in a tumor microenvironment by maneuvering sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA).

Authors:  Swatilekha Ghosh; Arghya Adhikary; Samik Chakraborty; Pinki Nandi; Suchismita Mohanty; Supriya Chakraborty; Pushpak Bhattacharjee; Sanhita Mukherjee; Salil Putatunda; Srabasti Chakraborty; Arijit Chakraborty; Gaurisankar Sa; Tanya Das; Parimal C Sen
Journal:  J Biol Chem       Date:  2012-07-31       Impact factor: 5.157

8.  Immune activation by combination human lymphokine-activated killer and dendritic cell therapy.

Authors:  E J West; K J Scott; V A Jennings; A A Melcher
Journal:  Br J Cancer       Date:  2011-08-16       Impact factor: 7.640

9.  Retroviral transduction of peptide stimulated t cells can generate dual t cell receptor-expressing (bifunctional) t cells reactive with two defined antigens.

Authors:  Alexander Langerman; Glenda G Callender; Michael I Nishimura
Journal:  J Transl Med       Date:  2004-12-08       Impact factor: 5.531

10.  Mechanisms of local immunosuppression in cutaneous melanoma.

Authors:  M E Polak; N J Borthwick; F G Gabriel; P Johnson; B Higgins; J Hurren; D McCormick; M J Jager; I A Cree
Journal:  Br J Cancer       Date:  2007-06-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.